MovDisordV3, PascalFrancis, Corpus, bibRecord, 000082

A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale

Identifieur interne : 000082 ( PascalFrancis/Corpus ); précédent : 000081; suivant : 000083

A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale

Auteurs : Susan H. Fox ; Tom H. Johnston ; QIN LI ; Jonathan Brotchie ; Erwan Bezard

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0393073

Descripteurs français

Pascal (Inist)
- Dyskinésie, Maladie de Parkinson, Syndrome choréique, Dystonie, Pathologie du système nerveux, Homme, Primates, Echelle d'évaluation, Lévodopa, Singe.

English descriptors

KwdEn :
- Chorea, Dyskinesia, Dystonia, Evaluation scale, Human, Levodopa, Monkey, Nervous system diseases, Parkinson disease, Primates.

Abstract

Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale`
A11	`01`	`1`		`@1 FOX (Susan H.)`
A11	`02`	`1`		`@1 JOHNSTON (Tom H.)`
A11	`03`	`1`		`@1 QIN LI`
A11	`04`	`1`		`@1 BROTCHIE (Jonathan)`
A11	`05`	`1`		`@1 BEZARD (Erwan)`
A14	`01`			`@1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network @2 Toronto, Ontario @3 CAN @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital @2 Toronto, Ontario @3 CAN @Z 1 aut.`
A14	`03`			`@1 Institute of Lab Animal Sciences, China Academy of Medical Sciences @2 Beijing @3 CHN @Z 3 aut. @Z 5 aut.`
A14	`04`			`@1 Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293 @2 Bordeaux @3 FRA @Z 5 aut.`
A14	`05`			`@1 CNRS, Institut des Maladies Neurodégénératives, UMR 5293 @2 Bordeaux @3 FRA @Z 5 aut.`
A20				`@1 1373-1378`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000502036870110`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 12-0393073`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Syndrome choréique @5 03`
C03	`03`	`X`	`ENG`	`@0 Chorea @5 03`
C03	`03`	`X`	`SPA`	`@0 Corea síndrome @5 03`
C03	`04`	`X`	`FRE`	`@0 Dystonie @5 04`
C03	`04`	`X`	`ENG`	`@0 Dystonia @5 04`
C03	`04`	`X`	`SPA`	`@0 Distonía @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Homme @5 09`
C03	`06`	`X`	`ENG`	`@0 Human @5 09`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`07`	`X`	`FRE`	`@0 Primates @2 NS @5 10`
C03	`07`	`X`	`ENG`	`@0 Primates @2 NS @5 10`
C03	`07`	`X`	`SPA`	`@0 Primates @2 NS @5 10`
C03	`08`	`X`	`FRE`	`@0 Echelle d'évaluation @5 11`
C03	`08`	`X`	`ENG`	`@0 Evaluation scale @5 11`
C03	`08`	`X`	`SPA`	`@0 Escala evaluación @5 11`
C03	`09`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 12`
C03	`09`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 12`
C03	`09`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 12`
C03	`10`	`X`	`FRE`	`@0 Singe @5 13`
C03	`10`	`X`	`ENG`	`@0 Monkey @5 13`
C03	`10`	`X`	`SPA`	`@0 Mono @5 13`
C07	`01`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`02`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`02`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 37`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`04`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`04`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`04`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 41`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`07`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`07`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`07`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
C07	`09`	`X`	`FRE`	`@0 Pathologie du muscle strié @5 44`
C07	`09`	`X`	`ENG`	`@0 Striated muscle disease @5 44`
C07	`09`	`X`	`SPA`	`@0 Músculo estriado patología @5 44`
N21				`@1 303`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0393073 INIST
ET :	A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale
AU :	FOX (Susan H.); JOHNSTON (Tom H.); QIN LI; BROTCHIE (Jonathan); BEZARD (Erwan)
AF :	Toronto Western Research Institute, Toronto Western Hospital, University Health Network/Toronto, Ontario/Canada (1 aut., 2 aut., 4 aut.); Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut.); Institute of Lab Animal Sciences, China Academy of Medical Sciences/Beijing/Chine (3 aut., 5 aut.); Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293/Bordeaux/France (5 aut.); CNRS, Institut des Maladies Neurodégénératives, UMR 5293/Bordeaux/France (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 11; Pp. 1373-1378; Bibl. 17 ref.
LA :	Anglais
EA :	Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale.
CC :	002B17; 002B02U01
FD :	Dyskinésie; Maladie de Parkinson; Syndrome choréique; Dystonie; Pathologie du système nerveux; Homme; Primates; Echelle d'évaluation; Lévodopa; Singe
FG :	Mammalia; Vertebrata; Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central; Pathologie du muscle strié
ED :	Dyskinesia; Parkinson disease; Chorea; Dystonia; Nervous system diseases; Human; Primates; Evaluation scale; Levodopa; Monkey
EG :	Mammalia; Vertebrata; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Striated muscle disease
SD :	Disquinesia; Parkinson enfermedad; Corea síndrome; Distonía; Sistema nervioso patología; Hombre; Primates; Escala evaluación; Levodopa; Mono
LO :	INIST-20953.354000502036870110
ID :	12-0393073

Links to Exploration step

Pascal:12-0393073

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qin Li" sort="Qin Li" uniqKey="Qin Li" last="Qin Li">QIN LI</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Lab Animal Sciences, China Academy of Medical Sciences</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Lab Animal Sciences, China Academy of Medical Sciences</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>CNRS, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0393073</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0393073 INIST</idno>
<idno type="RBID">Pascal:12-0393073</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000082</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qin Li" sort="Qin Li" uniqKey="Qin Li" last="Qin Li">QIN LI</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Lab Animal Sciences, China Academy of Medical Sciences</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Lab Animal Sciences, China Academy of Medical Sciences</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>CNRS, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chorea</term>
<term>Dyskinesia</term>
<term>Dystonia</term>
<term>Evaluation scale</term>
<term>Human</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Primates</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Maladie de Parkinson</term>
<term>Syndrome choréique</term>
<term>Dystonie</term>
<term>Pathologie du   système nerveux</term>
<term>Homme</term>
<term>Primates</term>
<term>Echelle d'évaluation</term>
<term>Lévodopa</term>
<term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FOX (Susan H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JOHNSTON (Tom H.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QIN LI</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BROTCHIE (Jonathan)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BEZARD (Erwan)</s1>
</fA11>
<fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institute of Lab Animal Sciences, China Academy of Medical Sciences</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>CNRS, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>1373-1378</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000502036870110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0393073</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome choréique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chorea</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Corea síndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Distonía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Echelle d'évaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Evaluation scale</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Escala evaluación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Singe</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Monkey</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Mono</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du muscle strié</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>44</s5>
</fC07>
<fN21><s1>303</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0393073 INIST</NO>
<ET>A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale</ET>
<AU>FOX (Susan H.); JOHNSTON (Tom H.); QIN LI; BROTCHIE (Jonathan); BEZARD (Erwan)</AU>
<AF>Toronto Western Research Institute, Toronto Western Hospital, University Health Network/Toronto, Ontario/Canada (1 aut., 2 aut., 4 aut.); Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut.); Institute of Lab Animal Sciences, China Academy of Medical Sciences/Beijing/Chine (3 aut., 5 aut.); Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293/Bordeaux/France (5 aut.); CNRS, Institut des Maladies Neurodégénératives, UMR 5293/Bordeaux/France (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 11; Pp. 1373-1378; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale.</EA>
<CC>002B17; 002B02U01</CC>
<FD>Dyskinésie; Maladie de Parkinson; Syndrome choréique; Dystonie; Pathologie du   système nerveux; Homme; Primates; Echelle d'évaluation; Lévodopa; Singe</FD>
<FG>Mammalia; Vertebrata; Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central; Pathologie du muscle strié</FG>
<ED>Dyskinesia; Parkinson disease; Chorea; Dystonia; Nervous system diseases; Human; Primates; Evaluation scale; Levodopa; Monkey</ED>
<EG>Mammalia; Vertebrata; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Striated muscle disease</EG>
<SD>Disquinesia; Parkinson enfermedad; Corea síndrome; Distonía; Sistema nervioso patología; Hombre; Primates; Escala evaluación; Levodopa; Mono</SD>
<LO>INIST-20953.354000502036870110</LO>
<ID>12-0393073</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000082 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000082 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0393073
   |texte=   A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale

A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri